Advertisement
OCS vs PRAX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCS is a Hold and PRAX is a StrongBuy.
| OCS | PRAX | OCS / PRAX | |
| Capitalization | 587M | 9.33B | 6% |
| EBITDA | -77.92M | -378.05M | 21% |
| Gain YTD | -47.121 | 13.517 | -349% |
| P/E Ratio | 63.08 | N/A | - |
| Revenue | 0 | 0 | - |
| Total Cash | 228M | 759M | 30% |
| Total Debt | 2.54M | 1.09M | 234% |
PRAX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 75 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 34 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| OCS | PRAX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 66% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 44% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 49% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 54% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 53% | 1 day ago 83% |
| Advances ODDS (%) | 26 days ago 74% | 11 days ago 86% |
| Declines ODDS (%) | 1 day ago 63% | 1 day ago 82% |
| BollingerBands ODDS (%) | 1 day ago 46% | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 58% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OCS’s FA Score shows that 0 FA rating(s) are green while PRAX’s FA Score has 0 green FA rating(s).
- OCS’s FA Score: 0 green, 5 red.
- PRAX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OCS’s TA Score shows that 5 TA indicator(s) are bullish while PRAX’s TA Score has 4 bullish TA indicator(s).
- OCS’s TA Score: 5 bullish, 5 bearish.
- PRAX’s TA Score: 4 bullish, 5 bearish.
Price Growth
OCS (@Biotechnology) experienced а -13.23% price change this week, while PRAX (@Biotechnology) price change was -4.90% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.
Reported Earning Dates
OCS is expected to report earnings on Nov 05, 2026.
PRAX is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-6.09% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
OCS and
Correlation & Price change
A.I.dvisor tells us that OCS and JSPR have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OCS and JSPR's prices will move in lockstep.
| Ticker / NAME | Correlation To OCS | 1D Price Change % | ||
|---|---|---|---|---|
| OCS | 100% | -6.63% | ||
| JSPR - OCS | 33% Poorly correlated | -5.77% | ||
| FTH - OCS | 32% Poorly correlated | -4.00% | ||
| GRI - OCS | 30% Poorly correlated | -2.06% | ||
| PRAX - OCS | 29% Poorly correlated | -1.18% | ||
| JBIO - OCS | 28% Poorly correlated | -6.53% | ||
More | ||||
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | -1.18% | ||
| BEAM - PRAX | 40% Loosely correlated | -1.56% | ||
| ANRO - PRAX | 38% Loosely correlated | +1.01% | ||
| BHVN - PRAX | 37% Loosely correlated | -0.63% | ||
| RAPP - PRAX | 35% Loosely correlated | +0.37% | ||
| VERU - PRAX | 35% Loosely correlated | -2.40% | ||
More | ||||